Home    Back

Nevanimibe    (DrugBank: Nevanimibe)

2 diseases
IDDisease name (Link within this page)Number of trials
75Cushing disease0
81Congenital adrenal hyperplasia3

75. Cushing disease    [ 191 clinical trials,   172 drugs,   (DrugBank: 48 drugs),   61 drug target genes,   121 drug target pathways]
Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 191 trial found

81. Congenital adrenal hyperplasia    [ 65 clinical trials,   77 drugs,   (DrugBank: 20 drugs),   11 drug target genes,   65 drug target pathways]
Searched query = "Congenital adrenal hyperplasia", "Congenital adrenal enzyme deficiency", "Congenial adrenal cortex enzyme deficiency", "Congenital Lipoid Adrenal Hyperplasia", "3β-Hydroxysteroid Dehydrogenase Deficiency", "21-Hydroxylase deficiency", "11β-Hydroxylase deficiency", "17α-Hydroxylase deficiency", "P450 oxidoreductase deficiency", "Aldosterone synthase deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 65 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2017-004878-34-FR
(EUCTR)		18/09/201824/04/2018A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal HyperplasiaA Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia
MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Nevanimibe Hydrochloride
Product Code: ATR-101
INN or Proposed INN: Nevanimibe hydrochloride
Other descriptive name: CI-984, 17AA70, PD 132301-2		Millendo Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes		24Phase 2France;Spain;Brazil;Israel
2EUCTR2017-004878-34-ES
(EUCTR)		01/08/201821/05/2018A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal HyperplasiaA Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia
MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Nevanimibe Hydrochloride
Product Code: ATR-101
INN or Proposed INN: Nevanimibe hydrochloride
Other descriptive name: CI-984, 17AA70, PD 132301-2		Millendo Therapeutics US, Inc.NULLNot RecruitingFemale: yes
Male: yes		24Phase 2France;Brazil;Spain;Israel
3NCT03669549
(ClinicalTrials.gov)		July 11, 201810/9/2018Nevanimibe HCl for the Treatment of Classic CAHA Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal HyperplasiaCongenital Adrenal HyperplasiaDrug: Nevanimibe hydrochlorideMillendo Therapeutics US, Inc.NULLTerminated18 Years80 YearsAll15Phase 2Brazil;Czechia;France;Israel;Spain